Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06525935
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-23
Brief Title:
A Study of CT-388 in Participants with Obesity or Overweight with At Least One Weight-Related Comorbidity
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Parallel Group Multi-Center Phase 2 Study to Evaluate the Efficacy Safety and Tolerability of Once-Weekly CT-388 Administered for 48 Weeks to Participants with Obesity or Overweight with At Least One Weight-Related Comorbidity
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multi-center randomized double-blind placebo-controlled parallel group dose-finding study to evaluate the efficacy and safety of CT-388 at low middle and high doses in participants with obesity or who are overweight with at least one weight-related comorbidity
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None